Literature DB >> 16247710

Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis.

Yuji Sakurai1, Hideyuki Motohashi, Ken Ogasawara, Tomohiro Terada, Satohiro Masuda, Toshiya Katsura, Noriko Mori, Motokazu Matsuura, Toshio Doi, Atsushi Fukatsu, Ken-ichi Inui.   

Abstract

PURPOSE: Our previous studies showed that the mRNA level of human organic anion transporter (hOAT) 3 in the kidney was correlated with the rate of elimination of an anionic antibiotic cefazolin. However, the correlation coefficient was not so high. In the present study, therefore, we enrolled more patients to examine whether additional factors were responsible for the correlation.
METHODS: hOAT mRNA levels in renal biopsy specimens were quantified using the real-time polymerase chain reaction method. The elimination rates for the free fraction of cefazolin were determined in patients with various renal diseases.
RESULTS: In the present study, the coefficient of correlation between the hOAT3 mRNA level and the elimination rates for the free fraction of cefazolin was not so high in the patients overall as in our previous study (r = 0.536). However, following the classification of renal diseases, a better correlation was obtained in patients with mesangial proliferative glomerulonephritis (r = 0.723). In contrast, multiple regression analyses including gender, age, and liver function did not result in any improvements in the correlation coefficients.
CONCLUSIONS: These results suggest that the hOAT3 mRNA level is a significant marker of pharmacokinetics with which to predict the rate of elimination of cefazolin in patients with mesangial proliferative glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16247710     DOI: 10.1007/s11095-005-8383-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  32 in total

Review 1.  IgA nephropathy: recent developments.

Authors:  Jürgen Floege; John Feehally
Journal:  J Am Soc Nephrol       Date:  2000-12       Impact factor: 10.121

Review 2.  The genetic polymorphism of drug transporters: functional analysis approaches.

Authors:  Toshihisa Ishikawa; Akira Tsuji; Kenichi Inui; Yoshimichi Sai; Naohiko Anzai; Morimasa Wada; Hitoshi Endou; Yasuhiro Sumino
Journal:  Pharmacogenomics       Date:  2004-01       Impact factor: 2.533

3.  Gene expression levels and immunolocalization of organic ion transporters in the human kidney.

Authors:  Hideyuki Motohashi; Yuji Sakurai; Hideyuki Saito; Satohiro Masuda; Yumiko Urakami; Maki Goto; Atsushi Fukatsu; Osamu Ogawa; Ken-Ichi Inui
Journal:  J Am Soc Nephrol       Date:  2002-04       Impact factor: 10.121

4.  High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1.

Authors:  S H Park; H J Choi; J H Lee; C H Woo; J H Kim; H J Han
Journal:  Kidney Int       Date:  2001-05       Impact factor: 10.612

5.  Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats.

Authors:  I Yano; T Ito; M Takano; K Inui
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

Review 6.  Mechanisms mediating renal secretion of organic anions and cations.

Authors:  J B Pritchard; D S Miller
Journal:  Physiol Rev       Date:  1993-10       Impact factor: 37.312

7.  Regulation by protein kinase C of organic anion transport driven by rat organic anion transporter 3 (rOAT3).

Authors:  M Takeda; T Sekine; H Endou
Journal:  Life Sci       Date:  2000       Impact factor: 5.037

Review 8.  Drug dosage in renal disease.

Authors:  L Dettli
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 9.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases.

Authors:  Yuji Sakurai; Hideyuki Motohashi; Harumasa Ueo; Satohiro Masuda; Hideyuki Saito; Masahiro Okuda; Noriko Mori; Motokazu Matsuura; Toshio Doi; Atsushi Fukatsu; Osamu Ogawa; Ken-ichi Inui
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

View more
  4 in total

1.  Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

Authors:  Yuichi Uwai; Hiroki Ida; Yoshie Tsuji; Toshiya Katsura; Ken-Ichi Inui
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

2.  Effects of metabolic acidosis on expression levels of renal drug transporters.

Authors:  Arong Gaowa; Hideyuki Motohashi; Toshiya Katsura; Ken-ichi Inui
Journal:  Pharm Res       Date:  2010-12-15       Impact factor: 4.200

Review 3.  Effects of drug transporters on volume of distribution.

Authors:  Anita Grover; Leslie Z Benet
Journal:  AAPS J       Date:  2009-04-28       Impact factor: 4.009

4.  RNA-seq of serial kidney biopsies obtained during progression of chronic kidney disease from dogs with X-linked hereditary nephropathy.

Authors:  Candice P Chu; Jessica A Hokamp; Rachel E Cianciolo; Alan R Dabney; Candice Brinkmeyer-Langford; George E Lees; Mary B Nabity
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.